title: Sapacitabine in the treatment of acute myeloid leukemia.
abstract: Prognosis of elderly patients with acute myeloid leukemia (AML) remains poor and new treatment approaches are urgently needed. A novel nucleoside analog sapacitabine has recently emerged as a feasible agent because of its oral administration and acceptable toxicity profile. Clinical efficacy of sapacitabine, both as a single agent and in combination, has been evaluated in elderly AML patients or AML patients unfit for standard intensive chemotherapy. Response rates varied from 15 to 45% in phase II studies. Sapacitabine was overall well-tolerated with gastrointestinal and myelosuppression-related complications were the most common side effects. Unfortunately, in a phase III study sapacitabine showed no clinical superiority as compared to low-dose cytarabine (LDAC) in patients with AML. Another large phase III study comparing the combination of sapacitabine with decitabine to decitabine alone is currently ongoing and is expected to be completed by the end of 2015 or by the first half of 2016.
authors.affiliation: a College of Medicine- Division of Hematology/Oncology , University of Florida , Gainesville , FL , USA.
authors.forename: Maxim
authors.initials: M
authors.lastname: Norkin
authors.affiliation: a College of Medicine- Division of Hematology/Oncology , University of Florida , Gainesville , FL , USA.
authors.forename: Ashley I
authors.initials: AI
authors.lastname: Richards
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003596:Cytosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D003596:Cytosine; C117959:sapacitabine
keywords: Sapacitabine; acute myeloid leukemia; novel nucleoside analogs